Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has issued an update.
On January 30, 2026, OKYO Pharma announced that Phase 2 proof-of-concept efficacy and safety data for its lead candidate urcosimod in neuropathic corneal pain have been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting in Washington, DC, scheduled for April 11, 2026. The acceptance, following a competitive review process, provides scientific validation and visibility for the positive pain-reduction signals and corneal nerve health trends seen in OKYO’s recently completed Phase 2 NCP trial, supporting the company’s strategy to advance urcosimod into a larger 150-patient Phase 2b/3 study in the first half of 2026 and potentially strengthen its positioning in the underserved market for NCP, which currently lacks FDA-approved therapies.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market that develops innovative investigational therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases. Its lead candidate, urcosimod (formerly OK-101), is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor on ocular immune and neuronal cells, and has shown anti-inflammatory and pain-reducing activity in both preclinical models and Phase 2 clinical trials for NCP and dry eye disease.
Average Trading Volume: 192,891
Technical Sentiment Signal: Hold
Current Market Cap: $82.37M
See more insights into OKYO stock on TipRanks’ Stock Analysis page.